Dominantly Inherited Alzheimer Network (DIAN)
ConditionAlzheimer's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Eligibility criteria
Qualifiers
Written informed consent obtained from participant and collateral source prior to any study-related procedures.
Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.
Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
Disqualifiers
Under age 18
Medical or psychiatric illness that would interfere in completing initial and follow-up visits
Requires nursing home level care
Has no one who can serve as a study informant
Trial design
Treatments tested in this trial
- Not listed
Trial groups
700 Participants
are grouped into 2 trial groupsSponsors and collaborators
Washington University School of Medicine
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov